Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyurea. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyurea SCHEMBL5745587 | 0.88 | — | — | |
| Hydroxyurea SCHEMBL93814 | 0.79 | LMNA (1.00) | TSHRNFKB1LMNACA5ACYP3A4 | |
| Hydroxyurea SCHEMBL5329855 | 0.79 | LMNA (1.00) | TSHRNFKB1LMNACA5ACYP3A4 | |
| Hydroxyurea SCHEMBL4004 | 0.79 | — | — | |
| Hydroxyurea SCHEMBL23274911 | 0.75 | — | — | |
| Hydroxyurea SCHEMBL15011410 | 0.75 | — | — | |
| Hydroxyurea SCHEMBL306433 | 0.75 | — | — | |
| Hydroxyurea SCHEMBL308240 | 0.75 | — | — | |
| Hydroxyurea SCHEMBL28783824 | 0.75 | — | — | |
| Hydroxyurea SCHEMBL28868410 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875486-A1 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20 | Joint Stock Company "Biocad" (RU) | 2021-09-08 | — | — | EP | disclosed |
| US-20200270345-A1 | Antibodies specific to CD47 and PD-L1 | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-08-27 | — | — | US | disclosed |
| EP-3693390-A1 | ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| CN-110402248-A | Azaindoles as HPK1 inhibitor | HOFFMANN LA ROCHE | 2019-11-01 | — | — | CN | disclosed |
| CN-105214086-B | Anti-VEGF antibodies combine the application for treating breast cancer with chemotherapy | 霍夫曼-拉罗奇有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110291102-A | Promote the method for t cell response | 国立卫生和医学研究所 | 2019-09-27 | — | — | CN | disclosed |
| CN-110267651-A | Method for enhancing immune checkpoint blockade therapy by modulating microbiome | 得克萨斯系统大学评议会 | 2019-09-20 | — | — | CN | disclosed |
| CN-110251668-A | Low-affinity blood-brain barrier receptor antibody and application thereof | 霍夫曼-拉罗奇有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110167599-A | Compound comprising introducing the self-sacrifice type linking group of beta galactose glycosides | 英托赛尔公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-105848723-B | Serine/threonine kinase inhibitor | 基因泰克公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-102131389-A | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH INC | 2011-07-20 | — | — | CN | disclosed |
| CN-102131390-A | Triazolopyridine jak inhibitor compounds and methods | GENENTECH INC | 2011-07-20 | — | — | CN | disclosed |
| CN-101945875-A | Azaindolizines and methods of use thereof | GENENTECH INC | 2011-01-12 | — | — | CN | disclosed |
| CN-101945870-A | 5-anilinoimidazopyridines and methods of use | GENENTECH INC | 2011-01-12 | — | — | CN | disclosed |
| CN-101918403-A | Pyrazolo-pyridines as tyrosine kinase inhibitor | ARRAY BIOPHARMA INC | 2010-12-15 | — | — | CN | disclosed |
| CN-101903387-A | 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH INC | 2010-12-01 | — | — | CN | disclosed |
| CN-101675053-A | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH INC | 2010-03-17 | — | — | CN | disclosed |
| CN-101605794-A | Azabenzofuranyl compounds and methods of use | GENENTECH INC (US) | 2009-12-16 | — | — | CN | disclosed |
| CN-101600720-A | Phosphoinositide 3-kinase inhibitor compounds and using method | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| CN-101583616-A | Aza-benzothiophenyl compounds and methods of use | GENENTECH INC (US) | 2009-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270345-A1 | Antibodies specific to CD47 and PD-L1 | CD47, CD274, PDCD1LG2 | TSHR 1426/4885NFKB1 1119/4885LMNA 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.